Am J Obstet Gynecol
- WU P, Zhou J, Zhang Y
Incorporation of BRCA1 testing into prenatal carrier screening for hereditary
breast and ovarian cancer prevention should take carrier rates into account.
Am J Obstet Gynecol. 2024 Dec 11:S0002-9378(24)01181.
BMC Cancer
- HUO C, Wu B, Ye D, Xu M, et al
New prognostic index for neoadjuvant chemotherapy outcome in patients with
advanced high-grade serous ovarian cancer.
BMC Cancer. 2024;24:1536.
- SCHMIDT M, Vernooij R, van Nuland M, Smeijsters E, et al
Impaired liver function: effect on paclitaxel toxicity, dose modifications and
overall survival.
BMC Cancer. 2024;24:1553.
Br J Cancer
- MERRITT MA, Abe SK, Islam MR, Rahman MS, et al
Reproductive factors and risk of epithelial ovarian cancer: results from the Asia
Cohort Consortium.
Br J Cancer. 2024 Dec 20. doi: 10.1038/s41416-024-02924.
- LIU C, Reger M, Fan H, Wang J, et al
Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the
prostate, lung, colorectal, and ovarian cancer screening trial.
Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
Cancer Lett
- LOMELI N, Pearre DC, Lepe J, Argueta DA, et al
N-acetylcysteine prevents cisplatin-induced cognitive impairments in an ovarian
cancer rat model.
Cancer Lett. 2024 Dec 18:217405. doi: 10.1016/j.canlet.2024.217405.
Clin Cancer Res
- SCHULTZ KAP, Nelson AT, Mallinger PHR, Harris AK, et al
DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and
Recommended Surveillance Strategies.
Clin Cancer Res. 2024;30:5681-5692.
Gynecol Oncol
- JANG EB, Lee AJ, So KA, Lee SJ, et al
Risk factors for the recurrence in patients with early endometrioid endometrial
cancer achieving complete remission for fertility-sparing hormonal treatment.
Gynecol Oncol. 2024;191:19-24.
- WAN S, Gao Y, Wu S, Wang H, et al
Somatic mutation of targeted sequencing identifies risk stratification in
advanced ovarian clear cell carcinoma.
Gynecol Oncol. 2024;191:56-66.
- RUSHTON T, Krause HB, Samec T, Elliott A, et al
Characterizing the genomic landscape through the lens of FOLR1 status in low and
high grade serous ovarian carcinoma.
Gynecol Oncol. 2024;191:80-85.
- YONEMORI K, Boni V, Min KG, Meniawy TM, et al
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and
combined with abemaciclib, in recurrent/advanced ER-positive endometrioid
endometrial cancer: Results from the phase 1a/1b EMBER study.
Gynecol Oncol. 2024;191:172-181.
- HICKEY M, Trainer AH, Krejany EO, Brand A, et al
What happens after menopause? (WHAM): A prospective controlled study of vasomotor
symptoms and menopause-related quality of life 24 months after premenopausal
risk-reducing salpingo-oophorectomy (RRSO).
Gynecol Oncol. 2024;191:201-211.
- GARCIA-DONAS J, Redondo A, Santaballa A, Garrigos L, et al
Phase II clinical trial assessing the efficacy of enzalutamide in advanced
non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
Gynecol Oncol. 2024;191:233-239.
- GRAVES S, Sullivan MW, Adkoli A, Zhou Q, et al
Association between genomic instability score and progression-free/overall
survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer.
Gynecol Oncol. 2024;192:120-127.
- AZAIS H, Brochard C, Taly V, Benoit L, et al
Prognostic value of circulating tumor DNA at diagnosis and its early decrease
after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial
ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
Gynecol Oncol. 2024;192:145-154.
- KONUMA M, Ikeda T, Mitoma T, Shirakawa S, et al
Effectiveness of exercise therapy on chemotherapy-induced peripheral neuropathy
in patients with ovarian cancer: A scoping review.
Gynecol Oncol. 2024;192:155-162.
Int J Cancer
- VERROU E, Koutoukoglou P, Kontana E, Gogolopoulos S, et al
Incidence, characteristics and outcome of therapy-related myeloid neoplasms in
women with epithelial ovarian cancer after exposure to poly-ADPribose polymerase
inhibitors: A cancer center experience.
Int J Cancer. 2024 Dec 17. doi: 10.1002/ijc.35299.
Int J Gynaecol Obstet
- ALSHWAYYAT S, Abo-Elnour DE, Dabash TY, Alshwayyat TA, et al
Personalized approach to malignant struma ovarii: Insights from a web-based
machine learning tool.
Int J Gynaecol Obstet. 2025;168:343-352.
Int J Gynecol Pathol
- WANG L, Vasudevaraja V, Tran I, Sukhadia P, et al
Novel Androgen Receptor Splice Variant 7 in Gynecologic Tumors.
Int J Gynecol Pathol. 2025;44:88-93.
- DE BOECK A, Nohr E, El-Hallani S, Ghatage P, et al
POLE-mutated Endometrial "Carcinosarcoma".
Int J Gynecol Pathol. 2025;44:72-78.
- DEL MUNDO MM, Aguilar M, Chen H, Niu S, et al
beta-catenin, PAX2, and PTEN Aberrancy Across the Spectrum of Endometrioid Ovarian
Lesions.
Int J Gynecol Pathol. 2025;44:79-87.
- CHRISTENSEN D, Ghafoor M, Goldberg A, De Cotiis DA, et al
Tumor Budding, Poorly Differentiated Clusters, and Stroma Percentage in Uterine
Endometrioid Carcinomas Are Morphologic Findings Associated With Adverse Clinical
Outcomes.
Int J Gynecol Pathol. 2025;44:49-55.
J Clin Oncol
- SCAMBIA G, Villalobos Valencia R, Colombo N, Cibula D, et al
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With
Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall
Survival Results.
J Clin Oncol. 2024 Dec 12:JCO2400933. doi: 10.1200/JCO.24.00933.
J Natl Cancer Inst
- ELZE L, van der Post RS, Vos JR, Mensenkamp AR, et al
Genomic instability in non-breast or ovarian malignancies of individuals with
germline pathogenic variants in BRCA1/2.
J Natl Cancer Inst. 2024;116:1904-1913.
Obstet Gynecol
- PENNINGTON KP, Pugh SL, Huh W, Walker JL, et al
Optimization of Timing for Risk-Reducing Salpingectomy and Oophorectomy.
Obstet Gynecol. 2025;145:21-30.
Oncogene
- ZHAI X, Shen N, Guo T, Wang J, et al
SPTLC2 drives an EGFR-FAK-HBEGF signaling axis to promote ovarian cancer
progression.
Oncogene. 2024 Dec 7. doi: 10.1038/s41388-024-03249.
PLoS Genet
- RIVERA IS, French JD, Bitar M, Sivakumaran H, et al
GWAS and 3D chromatin mapping identifies multicancer risk genes associated with
hormone-dependent cancers.
PLoS Genet. 2024;20:e1011490.
PLoS One
- WEINSTEIN SJ, Parisi D, Mondul AM, Layne TM, et al
Vitamin D binding protein genetic isoforms, serum vitamin D, and cancer risk in
the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
PLoS One. 2024;19:e0315252.
- RUSSO D, Spina A, Portella L, Bello AM, et al
The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human
ovarian cancer cells.
PLoS One. 2024;19:e0314735.
- PERAMPALAM P, McDonald JI, Dick FA
GO-CRISPR: A highly controlled workflow to discover gene essentiality in
loss-of-function screens.
PLoS One. 2024;19:e0315923.
- SENGUPTA D, Ali SN, Bhattacharya A, Mustafi J, et al
Correction: A deep hybrid learning pipeline for accurate diagnosis of ovarian
cancer based on nuclear morphology.
PLoS One. 2024;19:e0316114.
- WANG H, Han X, Niu S, Cheng H, et al
DFASGCNS: A prognostic model for ovarian cancer prediction based on dual fusion
channels and stacked graph convolution.
PLoS One. 2024;19:e0315924.
- LOPACINSKA-JORGENSEN J, Oliveira DVNP, Novotny GW, Hogdall CK, et al
Correction: Integrated microRNA and mRNA signatures associated with overall
survival in epithelial ovarian cancer.
PLoS One. 2024;19:e0315859.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016